The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...
Eli Lilly reports Q3 earnings on Wednesday. Stock up 58% in past year, potential to split to attract investors in growing ...
Type 2 diabetes drug Mounjaro and weight-loss drug Zepbound remained the brightest stars in Lilly's lineup. Mounjaro's sales ...
Q3 sales in weight loss drugs Mounjaro and Zepbound were more than 20% lower than consensus analyst forecasts, spooking ...
Mounjaro sales more than doubled to $3.11 billion from $1.41 billion a year ago. The U.S. pharma giant reported third-quarter ...